By 2020, approximately 1 in 19 Americans will be diagnosed with cancer. Without the rapid initiation and development of promising cancer clinical trials, the availability of potentially curative therapies for this large cohort of cancer patients will be severely limited.
The U.S. clinical trials enterprise is beset with a range of serious obstacles including growing complexity of trials, administrative barriers, regulatory constraints, expanding staffing requirements, increasing costs and lagging patient accrual.
To address these challenges, AACI has established a network for cancer center clinical research leaders – the AACI Clinical Research Initiative (CRI). The AACI CRI will examine and share best practices that promote the efficient operation of cancer center clinical research facilities, and will leverage the ability of the AACI cancer center network to advocate for improvement in the national clinical trials enterprise.
CRI is open exclusively to clinical research leaders from AACI’s 95 cancer centers. These leaders possess a comprehensive view or knowledge of their center’s entire clinical trials system, and they fill a variety of roles at their centers.
Keys to the success of this new AACI Clinical Research Initiative will be the development of new tools and methods to share information across the AACI network of cancer centers, and the dissemination of proven means of effectiveness and best practice models that lead to increased access to new cancer therapies.
Clinical trials are essential to the development of new therapeutic interventions and the clinical trials and data management operations of the nation’s cancer centers. They are crucial for the design and implementation of prevention, early detection and treatment modalities, and ultimately, cancer cures.